Navigation Links
Indevus Announces Management Changes
Date:6/12/2008

ions in urology and endocrinology. The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly, and a biodegradable ureteral stent used in association with the adjunctive treatment of kidney stones.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS and SUPPRELIN LA; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
2. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
3. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
4. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
5. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
6. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
7. Indevus Announces Allergan as New Partner for SANCTURA Brand
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results
10. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
(Date:1/14/2014)... MD (PRWEB) January 14, 2014 ... to developing innovative information technology solutions for patients, ... health care stakeholders, announced today the signing of ... US Food and Drug Administration (FDA). This ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Biomatrica, the leader in room,temperature biological sample stabilization, announced ... President of Sales and Marketing.,Biomatrica,s interim Vice President of ... of the company and will continue to serve as,an ... brings fourteen years of sales and marketing experience in,the ...
... operations during the first ... ... in US dollars, QUEBEC CITY, May 6 /PRNewswire-FirstCall/ - Atrium Innovations ... for health and nutrition industries, announced today,his financial results for the first ...
... 5 NeoGenomics, Inc. (OTC,Bulletin Board: NGNM) announced today that ... Wednesday, May 7, 2008., The Company has scheduled ... on May 7, 2008, at 11:00 AM EDT. Interested ... least,five minutes prior to the call. A replay of ...
Cached Biology Technology:Trisha Dowling Joins Biomatrica as Vice President, Sales and Marketing 2Atrium shows a strong financial performance for its first quarter 2Atrium shows a strong financial performance for its first quarter 3Atrium shows a strong financial performance for its first quarter 4Atrium shows a strong financial performance for its first quarter 5NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008 2
(Date:4/24/2014)... brain infection caused by fungus could now be treated in ... University of Liverpool scientists. , Cryptococcus a ... relatively neglected in medical research. They are found in ... East Asia and mainly affect people with weakened immune systems. ... The University research team has tested the effects of the ...
(Date:4/24/2014)... largest river turtle in North America, weighing in at ... Now researchers from Florida and the University of Vermont ... but three. , Examining museum specimens and wild turtles, ... reptile. , Once heavily hunted for turtle meat ... Soup in the 1960s the riverine populations have ...
(Date:4/23/2014)... allergies and other chronic inflammatory disorders among people of ... their reduced exposure to the microbes that thrive in ... The article, published in the journal Clinical & ... centers who have less access to green spaces may ... caused by immune system dysfunction. , When our immune ...
Breaking Biology News(10 mins):Treatment for deadly yeast disease reduced to 3 days 2Two new US turtle species described 2Two new US turtle species described 3Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3
... Brookhaven National Laboratory, the New York Structural Biology ... atomic crystal structure and functional mechanism of an ... as drugs, industrial chemicals, and toxic compounds from ... help scientists understand how these compounds are eliminated ...
... improve on milk, but animal scientists at the University ... transgenic goats, which carry the gene for an antibacterial ... bacteria in young goats and pigs that were fed ... one day lead to milk that protects infants and ...
... are preparing to stockpile vaccines against H5N1, the strain ... next flu pandemic. But will these vaccines remain effective ... the July 15 issue of The Journal of Infectious ... PhD, Robert G. Webster, PhD, and coworkers at St. ...
Cached Biology News:Scientists take 'snapshots' of enzyme action 2Transgenic goat's milk offers hope for tackling children's intestinal disease 2Transgenic goat's milk offers hope for tackling children's intestinal disease 3Experimental vaccine protects lab animals against several strains of H5N1 2
... through the extracellular matrix (ECM) is an ... cells initiate invasion by adhering to and ... Proteolytic enzymes, such as MMP collagenases, dissolve ... membrane) surrounding the blood vessels to allow ...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
Kit containing MACS equipment and reagents for immunopurification of proteins....
... of poor quality running into billions ... are under increasing pressure to reduce ... the microscopic distribution of ingredients is ... such as dissolution, stability, bio-availability and ...
Biology Products: